Fresenius Medical Care AG & Co. KGaA (FMS) – What Are Brokerages Thinking About This Stock?

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have received a consensus rating of “Reduce” from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation and seven have issued a hold recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $23.42.

A number of analysts have recently issued reports on FMS shares. Truist Financial decreased their target price on Fresenius Medical Care AG & Co. KGaA from $25.00 to $24.00 and set a “hold” rating for the company in a report on Monday, October 12th. BNP Paribas Exane downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 target price for the company. in a research report on Tuesday, July 28th. Sanford C. Bernstein raised their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a “market perform” rating in a report on Thursday, August 6th. Weiss Ratings upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 15th.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several large investors have recently made changes to their positions in the business. Mather Group LLC. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% in the 3rd quarter. Mather Group LLC. now owns 1,407 shares of the company’s stock valued at $31,000 after acquiring an additional 1,257 shares during the period. Farther Finance Advisors LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 39.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock worth $43,000 after purchasing an additional 538 shares during the period. Allworth Financial LP boosted its position in Fresenius Medical Care AG & Co. KGaA by 31.5% during the 2nd quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock worth $80,000 after purchasing an additional 850 shares during the period. Integrated Wealth Concepts LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at $91,000. Finally, EverSource Wealth Advisors LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 50.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock valued at $93,000 after purchasing an additional 1,383 shares in the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Price Performance

FMS stock opened at $21.93 on Tuesday. The company has a market cap of $11.78 billion, a PE ratio of 11.37, a price-to-earnings-growth ratio of 4.10 and a beta of 0.74. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average price of $22.60 and a two-hundred day moving average price of $22.88. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $20.02 and a 12-month high of $27.43.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. The company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. As a group, research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.